"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

A study has uncovered novel ancestry-specific genetic variants linked to multiple sclerosis (MS), offering new insights that ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...

Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Teva , the world's largest generic drugmaker, will be hit with an EU antitrust fine in the coming weeks for disparaging a ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...